Key Points
- ADMA Biologics director Jerrold Grossman bought 12,500 shares on May 11 at an average price of $8.01, a transaction worth about $100,125. After the purchase, he owned 501,384 shares valued at roughly $4.0 million.
- The company recently reported mixed quarterly results: earnings of $0.19 per share met expectations, but revenue of $114.49 million came in below estimates. Revenue was essentially flat year over year, while analysts still expect full-year EPS of 0.84.
- Wall Street sentiment has softened, with several firms cutting ratings or price targets. The stock currently has a consensus “Hold” rating and an average target price of $19.00, even as institutional investors own 75.68% of shares.
ADMA Biologics Inc (NASDAQ:ADMA - Get Free Report) Director Jerrold Grossman bought 12,500 shares of the stock in a transaction dated Monday, May 11th. The stock was bought at an average price of $8.01 per share, with a total value of $100,125.00. Following the purchase, the director owned 501,384 shares of the company's stock, valued at approximately $4,016,085.84. This represents a 2.56% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
ADMA Biologics Price Performance
ADMA stock opened at $8.41 on Wednesday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.93 and a current ratio of 6.95. ADMA Biologics Inc has a 1 year low of $7.21 and a 1 year high of $22.37. The firm has a market cap of $2.00 billion, a P/E ratio of 12.37 and a beta of 0.83. The stock has a 50-day simple moving average of $11.68 and a 200-day simple moving average of $15.33.
ADMA Biologics (NASDAQ:ADMA - Get Free Report) last posted its earnings results on Wednesday, May 6th. The biotechnology company reported $0.19 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.19. ADMA Biologics had a return on equity of 39.98% and a net margin of 32.43%.The business had revenue of $114.49 million during the quarter, compared to analyst estimates of $139.98 million. During the same quarter last year, the firm earned $0.11 earnings per share. The company's revenue for the quarter was down .3% compared to the same quarter last year. On average, equities analysts predict that ADMA Biologics Inc will post 0.84 earnings per share for the current fiscal year.
Institutional Investors Weigh In On ADMA Biologics
A number of hedge funds have recently bought and sold shares of ADMA. Westfield Capital Management Co. LP acquired a new stake in ADMA Biologics during the 3rd quarter valued at approximately $74,866,000. Janus Henderson Group PLC grew its stake in ADMA Biologics by 3,906.1% during the 4th quarter. Janus Henderson Group PLC now owns 3,936,419 shares of the biotechnology company's stock valued at $71,820,000 after purchasing an additional 3,838,158 shares in the last quarter. Capital Research Global Investors grew its stake in ADMA Biologics by 104.0% during the 4th quarter. Capital Research Global Investors now owns 6,637,472 shares of the biotechnology company's stock valued at $121,067,000 after purchasing an additional 3,383,559 shares in the last quarter. Caligan Partners LP acquired a new stake in ADMA Biologics during the 3rd quarter valued at approximately $38,653,000. Finally, UBS Group AG grew its stake in ADMA Biologics by 129.9% during the 4th quarter. UBS Group AG now owns 4,569,343 shares of the biotechnology company's stock valued at $83,345,000 after purchasing an additional 2,581,670 shares in the last quarter. Institutional investors and hedge funds own 75.68% of the company's stock.
Analysts Set New Price Targets
ADMA has been the subject of a number of recent research reports. Zacks Research lowered ADMA Biologics from a "strong-buy" rating to a "hold" rating in a research note on Monday, April 27th. Wall Street Zen lowered ADMA Biologics from a "buy" rating to a "hold" rating in a research note on Monday, May 4th. Mizuho lowered their target price on ADMA Biologics from $24.00 to $20.00 and set an "outperform" rating for the company in a research note on Thursday, May 7th. Cantor Fitzgerald restated a "neutral" rating on shares of ADMA Biologics in a research note on Thursday, March 26th. Finally, Canaccord Genuity Group lowered their price objective on ADMA Biologics from $21.00 to $18.00 and set a "buy" rating for the company in a research note on Thursday, May 7th. Two analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $19.00.
View Our Latest Stock Analysis on ADMA Biologics
ADMA Biologics Company Profile
(
Get Free Report)
ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.
The company's marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
